Debiopharm reveals phase 1/2 GaLuCi research results
The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate
Read More
Tag: galuci
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
